Boston Therapeutics (OTCMKTS:BTHE) and Evelo Biosciences (OTCMKTS:EVLO) Critical Review

Boston Therapeutics (OTCMKTS:BTHE) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.


This table compares Boston Therapeutics and Evelo Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Therapeutics -8,042.35% N/A -104.81%
Evelo Biosciences N/A -71.77% -58.10%

Valuation & Earnings

This table compares Boston Therapeutics and Evelo Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boston Therapeutics $30,000.00 30.01 -$3.60 million N/A N/A
Evelo Biosciences N/A N/A -$56.94 million ($2.78) -2.35

Boston Therapeutics has higher revenue and earnings than Evelo Biosciences.

Insider & Institutional Ownership

86.2% of Evelo Biosciences shares are held by institutional investors. 15.7% of Boston Therapeutics shares are held by company insiders. Comparatively, 59.1% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Boston Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Boston Therapeutics and Evelo Biosciences, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Therapeutics 0 0 0 0 N/A
Evelo Biosciences 0 1 3 0 2.75

Evelo Biosciences has a consensus price target of $17.67, suggesting a potential upside of 170.55%. Given Evelo Biosciences’ higher probable upside, analysts clearly believe Evelo Biosciences is more favorable than Boston Therapeutics.


Evelo Biosciences beats Boston Therapeutics on 7 of the 10 factors compared between the two stocks.

Boston Therapeutics Company Profile

Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also develops OxyFex, an oxygen delivery agent for ischemia and trauma for blood loss during surgery in veterinary medicine applications. In addition, it produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Boston Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Therapeutics and related companies with's FREE daily email newsletter.